


CORRECTION

Open Access



Correction to: Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies

Dunhui Li^{1,2†}, Craig Stewart McIntosh^{1,2†}, Frank Louis Mastaglia^{1,2}, Steve Donald Wilton^{1,2} and May Thandar Aung-Htut^{1,2*} 

Correction to: *Translational Neurodegeneration* (2021) 10:16
<https://doi.org/10.1186/s40035-021-00240-7>

Following publication of the original article [1], the authors would like to correct a formula from “T > C” to “C > T” in two paragraphs.

1. In the third paragraph of the section **Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)**, the correct sentence should be:

However, the synonymous C > T substitution in SMN2 exon 7 alters an exonic splicing enhancer into an exonic splicing silencer, which predominantly leads to an unstable transcript missing exon 7.

2. In the fourth paragraph of the section **Splice-switching AOs**, the correct sentence should be:

The C > T substitution in SMN2 creates an exon-splicing silencer and leads to the omission of exon 7 and an unstable SMN protein that is subject to rapid ubiquitin-proteasome degradation.

In addition, the authors identified an error in Fig. 4. The correct figure is given below:

The original article [1] has been corrected.

The original article can be found online at <https://doi.org/10.1186/s40035-021-00240-7>.


*Correspondence: m.aung-htut@murdoch.edu.au

†Dunhui Li and Craig Stewart McIntosh contributed equally to this work

¹ Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Western Australia, Australia
Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



Author details

¹Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Western Australia, Australia. ²Perron Institute for Neurological and Translational Science, Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Perth, Western Australia, Australia.

Reference

1. Li, et al. *Transl Neurodegener.* 2021;10:16.

Published online: 25 October 2021